Whereas no significant differences were observed in the number of TILs nor in the expression of costimulatory or coinhibitory molecules, or in the percentage of Tregs; mice bearing galectin-1-silenced tumors showed higher survival rates, and this effect was partially reversed when CD8+ T cells were depleted in vivo, thus underscoring the importance of cytotoxic effector T cells in GBM antitumor immunity. This evidence concerns the gene LGALS1 and glioblastoma.